Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India

Post Date: 
Clinical Sites: 
Emerging Infectious Diseases


We provide an overview of the epidemiology and clinical course of mucormycosis in the coronavirus disease (COVID-19) pandemic era. We conducted a retrospective chart review of 178 patients with clinical or diagnostic, endoscopically or histopathologically confirmed rhino-sino-orbital or cerebral mucormycosis after COVID-19 treatment during the second wave of COVID-19 in Pune, India. Median time to symptom onset from COVID-19 detection was 28 days. Moderate or severe COVID-19 was seen in 73% of patients and diabetes in 74.2%. A total of 52.8% received steroids. Eschar over or inside the nose was seen in 75%, but baseline clinical and laboratory parameters were mostly unremarkable. Bone penetration was present in ≈90% of cases, 30% had soft-tissue swelling of the pterygopalatine fossa and 7% had cavernous sinus thrombosis, and 60% had multifocal mucormycosis. Of the 178 study cases, 151 (85%) underwent surgical debridement. Twenty-six (15%) died, and 16 (62%) of those had multifocal mucormycosis.

Joshi S, Telang R, Tambe M, Havaldar R, Sane M, Shaikh A, Roy C, Yathati K, Sonawale S, Borkar R, Magar R, Bhitkar H, Shitole S, Nakate L, Kudrimoti J, Mave V. Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India. Emerg Infect Dis. 2022 Jan;28(1):1-8. doi: 10.3201/eid2801.211636. Epub 2021 Sep 29. PMID: 34586055; PMCID: PMC8714213.